Trial Outcomes & Findings for Lidocaine For Neuroprotection During Cardiac Surgery (NCT NCT00938964)

NCT ID: NCT00938964

Last Updated: 2019-05-10

Results Overview

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

550 participants

Primary outcome timeframe

Preoperative to 6 weeks after surgery

Results posted on

2019-05-10

Participant Flow

550 participants consented; 478 participants were randomized.

Participant milestones

Participant milestones
Measure
Lidocaine
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Overall Study
STARTED
241
237
Overall Study
COMPLETED
211
209
Overall Study
NOT COMPLETED
30
28

Reasons for withdrawal

Reasons for withdrawal
Measure
Lidocaine
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Overall Study
Death
3
3
Overall Study
Lost to Follow-up
2
3
Overall Study
Withdrawal by Subject
22
18
Overall Study
Found to Meet Exclusion Criteria
3
4

Baseline Characteristics

Lidocaine For Neuroprotection During Cardiac Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Total
n=420 Participants
Total of all reporting groups
Age, Continuous
66.9 years
STANDARD_DEVIATION 9.1 • n=99 Participants
66.5 years
STANDARD_DEVIATION 9.5 • n=107 Participants
66.7 years
STANDARD_DEVIATION 9.3 • n=206 Participants
Sex: Female, Male
Female
60 Participants
n=99 Participants
49 Participants
n=107 Participants
109 Participants
n=206 Participants
Sex: Female, Male
Male
151 Participants
n=99 Participants
160 Participants
n=107 Participants
311 Participants
n=206 Participants
Region of Enrollment
United States
211 Participants
n=99 Participants
209 Participants
n=107 Participants
420 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Preoperative to 6 weeks after surgery

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change
0.07 units on a scale
Standard Deviation 0.32
0.07 units on a scale
Standard Deviation 0.37

PRIMARY outcome

Timeframe: Preoperative to 6 weeks after surgery

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome
87 Participants
83 Participants

SECONDARY outcome

Timeframe: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Outcome measures

Outcome measures
Measure
Lidocaine
n=105 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=97 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Transcerebral Activation Gradients of Platelets
Baseline
-0.03 Mean linear fluorescence intensity-MLFI
Standard Deviation 0.79
0.35 Mean linear fluorescence intensity-MLFI
Standard Deviation 1.91
Transcerebral Activation Gradients of Platelets
Cross-clamp removal
0.03 Mean linear fluorescence intensity-MLFI
Standard Deviation 1.21
0.43 Mean linear fluorescence intensity-MLFI
Standard Deviation 1.44
Transcerebral Activation Gradients of Platelets
End of Bypass
0.33 Mean linear fluorescence intensity-MLFI
Standard Deviation 3.25
0.05 Mean linear fluorescence intensity-MLFI
Standard Deviation 2.65
Transcerebral Activation Gradients of Platelets
6 hours post cross-clamp removal
0.37 Mean linear fluorescence intensity-MLFI
Standard Deviation 2.65
0.27 Mean linear fluorescence intensity-MLFI
Standard Deviation 1.07

SECONDARY outcome

Timeframe: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Outcome measures

Outcome measures
Measure
Lidocaine
n=105 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=97 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Transcerebral Activation Gradients of Neutrophils
Baseline
-2.02 Mean linear fluorescence intensity-MLFI
Standard Deviation 8.15
-0.08 Mean linear fluorescence intensity-MLFI
Standard Deviation 9.17
Transcerebral Activation Gradients of Neutrophils
Cross-clamp removal
0.56 Mean linear fluorescence intensity-MLFI
Standard Deviation 6.82
0.17 Mean linear fluorescence intensity-MLFI
Standard Deviation 5.53
Transcerebral Activation Gradients of Neutrophils
End of Bypass
0.58 Mean linear fluorescence intensity-MLFI
Standard Deviation 4.54
1.19 Mean linear fluorescence intensity-MLFI
Standard Deviation 6.76
Transcerebral Activation Gradients of Neutrophils
6 hours post cross-clamp removal
1.04 Mean linear fluorescence intensity-MLFI
Standard Deviation 7.08
-0.68 Mean linear fluorescence intensity-MLFI
Standard Deviation 8.61

SECONDARY outcome

Timeframe: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects.

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Outcome measures

Outcome measures
Measure
Lidocaine
n=105 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=97 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Transcerebral Activation Gradients of Monocytes
Baseline
-4.22 Mean linear fluorescence intensity-MLFI
Standard Deviation 19.10
-0.04 Mean linear fluorescence intensity-MLFI
Standard Deviation 17.78
Transcerebral Activation Gradients of Monocytes
Cross-clamp removal
-2.46 Mean linear fluorescence intensity-MLFI
Standard Deviation 16.94
1.83 Mean linear fluorescence intensity-MLFI
Standard Deviation 16.80
Transcerebral Activation Gradients of Monocytes
End of Bypass
-0.34 Mean linear fluorescence intensity-MLFI
Standard Deviation 19.57
2.64 Mean linear fluorescence intensity-MLFI
Standard Deviation 15.69
Transcerebral Activation Gradients of Monocytes
6 hours post cross-clamp removal
1.21 Mean linear fluorescence intensity-MLFI
Standard Deviation 15.08
0.54 Mean linear fluorescence intensity-MLFI
Standard Deviation 13.69

SECONDARY outcome

Timeframe: Baseline to 6 hours post cross-clamp removal

Population: Planned substudy, that was analyzed after 202 enrolled subjects.

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Outcome measures

Outcome measures
Measure
Lidocaine
n=105 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=97 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Transcerebral Activation Gradient of Platelet-neutrophil Conjugates
Baseline
-0.15 Mean linear fluorescence intensity-MLFI
Standard Deviation 9.64
-0.43 Mean linear fluorescence intensity-MLFI
Standard Deviation 8.40
Transcerebral Activation Gradient of Platelet-neutrophil Conjugates
Cross-clamp removal
0.02 Mean linear fluorescence intensity-MLFI
Standard Deviation 4.33
-0.73 Mean linear fluorescence intensity-MLFI
Standard Deviation 3.97
Transcerebral Activation Gradient of Platelet-neutrophil Conjugates
End of Bypass
-0.73 Mean linear fluorescence intensity-MLFI
Standard Deviation 4.99
-0.40 Mean linear fluorescence intensity-MLFI
Standard Deviation 5.12
Transcerebral Activation Gradient of Platelet-neutrophil Conjugates
6 hours post cross-clamp removal
-0.10 Mean linear fluorescence intensity-MLFI
Standard Deviation 5.40
0.19 Mean linear fluorescence intensity-MLFI
Standard Deviation 4.73

SECONDARY outcome

Timeframe: 1 year after surgery

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Cognitive Function From Baseline
0.09 units on a scale
Standard Deviation 0.34
0.07 units on a scale
Standard Deviation 0.34

SECONDARY outcome

Timeframe: baseline, 6-weeks

The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done "with no difficulty" receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Duke Activity Status Index (DASI)
-10.98 units on a scale
Standard Deviation 15.4
-11.67 units on a scale
Standard Deviation 16.8

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done "with no difficulty" receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Duke Activity Status Index (DASI)
6.3 units on a scale
Standard Deviation 18.3
6.96 units on a scale
Standard Deviation 16.9

SECONDARY outcome

Timeframe: baseline, 6-weeks

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)
0.05 units on a scale
Standard Deviation 0.5
0.04 units on a scale
Standard Deviation 0.5

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)
0.05 units on a scale
Standard Deviation 0.70
0.07 units on a scale
Standard Deviation 0.60

SECONDARY outcome

Timeframe: baseline, 6-weeks

Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as "I had crying spells" and "I felt lonely." Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Center for Epidemiological Studies Depression Scale (CES-D)
0.57 units on a scale
Standard Deviation 7.5
0.16 units on a scale
Standard Deviation 8.3

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as "I had crying spells" and "I felt lonely." Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Center for Epidemiological Studies Depression Scale (CES-D)
-1.27 units on a scale
Standard Deviation 7.7
-0.89 units on a scale
Standard Deviation 7.9

SECONDARY outcome

Timeframe: baseline, 6-weeks

Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as "I feel nervous" and "I feel worried." These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from "not at all" to "very much so." Scores range from 20 to 80, with higher scores indicating greater anxiety.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Spielberger State Anxiety Inventory (STAI)
-7.12 units on a scale
Standard Deviation 12.1
-6.31 units on a scale
Standard Deviation 11.4

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as "I feel nervous" and "I feel worried." These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from "not at all" to "very much so." Scores range from 20 to 80, with higher scores indicating greater anxiety.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Spielberger State Anxiety Inventory (STAI)
-6.70 units on a scale
Standard Deviation 12.7
-6.39 units on a scale
Standard Deviation 10.3

SECONDARY outcome

Timeframe: baseline, 6-weeks

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Symptom Limitations
-0.67 units on a scale
Standard Deviation 4.0
-0.8 units on a scale
Standard Deviation 3.9

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Symptom Limitations
-1.39 units on a scale
Standard Deviation 3.8
-1.48 units on a scale
Standard Deviation 3.8

SECONDARY outcome

Timeframe: baseline, 6-weeks

Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., "Could you prepare your own meals?" "Could you drive a car?"). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)
2.46 units on a scale
Standard Deviation 4.2
2.1 units on a scale
Standard Deviation 3.9

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., "Could you prepare your own meals?" "Could you drive a car?"). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)
-0.15 units on a scale
Standard Deviation 2.1
-0.31 units on a scale
Standard Deviation 2.6

SECONDARY outcome

Timeframe: baseline, 6-weeks

Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are "I forget errands I planned to do" and "I fail to recognize people I know." Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in the Cognitive Difficulties Scale
-3 units on a scale
Standard Deviation 14.6
-3.21 units on a scale
Standard Deviation 15.9

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are "I forget errands I planned to do" and "I fail to recognize people I know." Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in the Cognitive Difficulties Scale
-0.46 units on a scale
Standard Deviation 16.1
-1.02 units on a scale
Standard Deviation 17

SECONDARY outcome

Timeframe: baseline, 6-weeks

Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is "a special person who is around when I am in need" and "my family really tries to help me." Choices range from "very strongly disagree" to "very strongly agree." Items are summed for a range of 12 to 84, with a high score meaning more social support.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Perceived Social Support
1.23 units on a scale
Standard Deviation 14
-0.49 units on a scale
Standard Deviation 13.9

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is "a special person who is around when I am in need" and "my family really tries to help me." Choices range from "very strongly disagree" to "very strongly agree." Items are summed for a range of 12 to 84, with a high score meaning more social support.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Perceived Social Support
0.71 units on a scale
Standard Deviation 13.4
-1.16 units on a scale
Standard Deviation 12.9

SECONDARY outcome

Timeframe: baseline, 6-weeks

Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are "How often do you talk on the telephone with friends and relatives?" and "How often do you attend meetings of social groups, clubs, or civic organizations?" Scores range from 8 to 32. A lower score indicates more social activity.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Social Activity
0.95 units on a scale
Standard Deviation 3.4
1.59 units on a scale
Standard Deviation 3.2

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are "How often do you talk on the telephone with friends and relatives?" and "How often do you attend meetings of social groups, clubs, or civic organizations?" Scores range from 8 to 32. A lower score indicates more social activity.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Social Activity
-0.20 units on a scale
Standard Deviation 3.2
0.03 units on a scale
Standard Deviation 3.4

SECONDARY outcome

Timeframe: baseline, 6-weeks

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Study 36-Item Short Form Health Survey (SF-36)
6-Week Change Work activities
2.71 units on a scale
Standard Deviation 4.9
3 units on a scale
Standard Deviation 4.3
Change in Study 36-Item Short Form Health Survey (SF-36)
6-Week Change General health perception
-0.004 units on a scale
Standard Deviation 1.3
-0.03 units on a scale
Standard Deviation 1.2

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Study 36-Item Short Form Health Survey (SF-36)
1 year Change Work Activities
-1.37 units on a scale
Standard Deviation 4.3
-1.42 units on a scale
Standard Deviation 4.1
Change in Study 36-Item Short Form Health Survey (SF-36)
1 year Change General health perception
-0.28 units on a scale
Standard Deviation 1.2
-0.43 units on a scale
Standard Deviation 1.1

SECONDARY outcome

Timeframe: baseline, 6-weeks

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.

Outcome measures

Outcome measures
Measure
Lidocaine
n=211 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=209 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)
0.04 units on a scale
Standard Deviation 1.10
-0.01 units on a scale
Standard Deviation 1.3

SECONDARY outcome

Timeframe: baseline, 1-year

Population: There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis.

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.

Outcome measures

Outcome measures
Measure
Lidocaine
n=185 Participants
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=192 Participants
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)
0.02 units on a scale
Standard Deviation 1.10
-0.02 units on a scale
Standard Deviation 1.20

Adverse Events

Lidocaine

Serious events: 105 serious events
Other events: 34 other events
Deaths: 6 deaths

Placebo

Serious events: 103 serious events
Other events: 34 other events
Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure
Lidocaine
n=241 participants at risk
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=237 participants at risk
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Blood and lymphatic system disorders
Acute Blood Loss anemia
1.7%
4/241 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.3%
3/237 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Renal and urinary disorders
Acute Urinary Retention
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Renal and urinary disorders
Acute Kidney Injury
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.5%
6/237 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Immune system disorders
Anaphylatic or Anaphylactoid rxn
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Aphasia
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Atrial Dysrhythmia - Atrial Fibrillation
17.0%
41/241 • Number of events 41 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
17.3%
41/237 • Number of events 41 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Atrial Dysrhythmia -Sinus Bradycardia
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.7%
4/237 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
AV Block
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Bacermia/sepsis
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Blood and lymphatic system disorders
Bleeding
2.5%
6/241 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
3.0%
7/237 • Number of events 7 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Bradycardia
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Bronchitis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Cardiac Arrest
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Cardiac Tamponade
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Cardiogenic Shock
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.7%
4/237 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Blood and lymphatic system disorders
Chylothorax
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Blood and lymphatic system disorders
Coagulopathy
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Complete heart block
2.9%
7/241 • Number of events 7 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.5%
6/237 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Confusion/encephalopathy
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Congestive Heart Failure
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Continuous coma
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Vascular disorders
Deep Vein Thrombosis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Injury, poisoning and procedural complications
Diaphragmic tear
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Dysphagia
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Immune system disorders
Fever of Non-Specified Origin
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
General disorders
Fluid overload
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Gastrointestinal disorders
GI Bleed
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Heart attack-hospitalization
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Heart failure
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Renal and urinary disorders
Hematuria
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Hemoptysis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Hemorrhagic shock
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Hemothorax
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Haemophilus Influenzae
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Metabolism and nutrition disorders
Hyperkalemia
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Hypertension
2.5%
6/241 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Metabolism and nutrition disorders
Hypokalemia
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Metabolism and nutrition disorders
Hyponatremia
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Hypotension
3.3%
8/241 • Number of events 8 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
3.0%
7/237 • Number of events 7 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Hypothermia
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Hypovolemic shock
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Hypoxemia
1.2%
3/241 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Gastrointestinal disorders
Ileus
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.5%
6/237 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Infection
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Gastrointestinal disorders
Irritable bowel syndrome
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Junctional rhythm
2.1%
5/241 • Number of events 5 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.3%
3/237 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Metabolism and nutrition disorders
Lactic acidosis
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Left brachial embolectomy
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Left bundle branch block
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Left pleural effusion thoracentesis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Left vocal cord palsy
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Leukocytosis
3.3%
8/241 • Number of events 8 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
3.0%
7/237 • Number of events 7 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
LVAD
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Metabolism and nutrition disorders
Metabolic acidosis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
MRSA
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Gastrointestinal disorders
Nausea/Vomiting/Constipation
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.7%
4/237 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Pacemaker Placement
2.5%
6/241 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
3.4%
8/237 • Number of events 8 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
General disorders
Pain
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Nervous system disorders
Parkinson's disease
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
PEA Arrest
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Pericarditis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.3%
3/237 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Immune system disorders
Phlebitis
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Pleural Effusion
2.1%
5/241 • Number of events 5 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.5%
6/237 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Pneumonia
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Pneumothorax
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
General disorders
Prolonged hospitalization
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Metabolism and nutrition disorders
Protein malnutrition
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Pulmonary congestion
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Injury, poisoning and procedural complications
Pulmonary contusion
1.2%
3/241 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Pulmonary Edema
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.1%
5/237 • Number of events 5 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Pulseless electrical activity
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
General disorders
re-admission after fall
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Reexploration For Bleeding
1.7%
4/241 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
1.7%
4/237 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Reintubation
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Renal and urinary disorders
Renal Failure
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Renal and urinary disorders
Renal Insufficiency
2.9%
7/241 • Number of events 7 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.1%
5/237 • Number of events 5 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Respiratory Distress
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Respiratory Failure
1.7%
4/241 • Number of events 4 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.5%
6/237 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Shock
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Sinus tachycardia
1.2%
3/241 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Sternal Wound Infection
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Vascular disorders
Stroke
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.5%
6/237 • Number of events 6 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Subcutaneous Air
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Suprapubic catheter placement
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Syncope
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Surgical and medical procedures
Thoracentesis
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.84%
2/237 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Blood and lymphatic system disorders
Thrombocytopenia
3.3%
8/241 • Number of events 8 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
3.4%
8/237 • Number of events 8 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Thrush
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Immune system disorders
Tranfusion rxn
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Trifascicular block
0.00%
0/241 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Renal and urinary disorders
Urinary Tract Infection
1.2%
3/241 • Number of events 3 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.42%
1/237 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Respiratory, thoracic and mediastinal disorders
Ventilation > 48hr
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Infections and infestations
Ventilator associated pneumonia
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Ventricular Dysrhythmia - Ventricular Tachycardia
0.83%
2/241 • Number of events 2 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
2.1%
5/237 • Number of events 5 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
Cardiac disorders
Ventricular ectopy
0.41%
1/241 • Number of events 1 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
0.00%
0/237 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.

Other adverse events

Other adverse events
Measure
Lidocaine
n=241 participants at risk
Lidocaine infusion for 48 hours Lidocaine: Lidocaine versus placebo infusion for 48 hours
Placebo
n=237 participants at risk
Normal saline infusion for 48 hours Placebo: Lidocaine versus placebo infusion for 48 hours
Cardiac disorders
Atrial Dysrhythmia - Atrial Fibrillation
14.1%
34/241 • Number of events 34 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.
14.3%
34/237 • Number of events 34 • Adverse events were collected until hospital discharge (approximately 4 -10 days) . Serious Adverse Events were reported up to one year.

Additional Information

Joseph Mathew, M.D

Duke University Health System

Phone: 919-681-6646

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place